- Home
- PEN vs BLCO Comparison
PEN vs BLCO Comparison
Compare PEN & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- BLCO
- Stock Information
- Founded
- PEN 2004
- BLCO 1853
- Country
- PEN United States
- BLCO Canada
- Employees
- PEN N/A
- BLCO N/A
- Industry
- PEN Medical/Dental Instruments
- BLCO Ophthalmic Goods
- Sector
- PEN Health Care
- BLCO Health Care
- Exchange
- PEN Nasdaq
- BLCO Nasdaq
- Market Cap
- PEN 9.1B
- BLCO 7.0B
- IPO Year
- PEN 2015
- BLCO 2022
- Fundamental
- Price
- PEN $241.10
- BLCO $18.24
- Analyst Decision
- PEN Buy
- BLCO Buy
- Analyst Count
- PEN 15
- BLCO 12
- Target Price
- PEN $259.86
- BLCO $20.91
- AVG Volume (30 Days)
- PEN 316.9K
- BLCO 547.4K
- Earning Date
- PEN 02-20-2025
- BLCO 02-19-2025
- Dividend Yield
- PEN N/A
- BLCO N/A
- EPS Growth
- PEN N/A
- BLCO N/A
- EPS
- PEN 0.89
- BLCO N/A
- Revenue
- PEN $1,163,776,000.00
- BLCO $4,684,000,000.00
- Revenue This Year
- PEN $13.55
- BLCO $17.39
- Revenue Next Year
- PEN $14.48
- BLCO $6.18
- P/E Ratio
- PEN $268.19
- BLCO N/A
- Revenue Growth
- PEN 16.96
- BLCO 18.01
- 52 Week Low
- PEN $148.00
- BLCO $13.16
- 52 Week High
- PEN $277.34
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- PEN 52.20
- BLCO 43.74
- Support Level
- PEN $234.55
- BLCO $17.63
- Resistance Level
- PEN $241.89
- BLCO $18.24
- Average True Range (ATR)
- PEN 6.40
- BLCO 0.44
- MACD
- PEN -1.31
- BLCO -0.01
- Stochastic Oscillator
- PEN 36.55
- BLCO 48.06
About PEN Penumbra Inc.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.